Alicia Beeghly-Fadiel

List of Publications by Year
in descending order

82 papers	2,676 citations	218677 26 h-index	214800 47 g-index
84 all docs	84 docs citations	84 times ranked	6141 citing authors

#	Article	IF	Citations
1	Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. Nature Genetics, 2015, 47, 1294-1303.	21.4	357
2	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
3	Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. Lancet Oncology, The, 2011, 12, 477-488.	10.7	241
4	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	21.4	120
5	Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent. PLoS Medicine, 2016, 13, e1002105.	8.4	118
6	Association of Obesity-related Genetic Variants With Endometrial Cancer Risk: A Report From the Shanghai Endometrial Cancer Genetics Study. American Journal of Epidemiology, 2011, 174, 1115-1126.	3.4	65
7	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Research, 2018, 78, 5419-5430.	0.9	54
8	Fineâ€scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. International Journal of Cancer, 2016, 139, 1303-1317.	5.1	51
9	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. Cancer Research, 2019, 79, 505-517.	0.9	49
10	Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk. Journal of the National Cancer Institute, 2021, 113, 329-337.	6.3	45
11	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). Clinical Cancer Research, 2020, 26, 5411-5423.	7.0	43
12	A Mendelian randomization analysis of circulating lipid traits and breast cancer risk. International Journal of Epidemiology, 2020, 49, 1117-1131.	1.9	41
13	Polymorphisms in tissue inhibitors of metalloproteinasesâ€2 and â€3 and breast cancer susceptibility and survival. International Journal of Cancer, 2009, 125, 844-850.	5.1	40
14	Common MMP-7 Polymorphisms and Breast Cancer Susceptibility: A Multistage Study of Association and Functionality. Cancer Research, 2008, 68, 6453-6459.	0.9	39
15	Genetic polymorphisms in the MMPâ€7 gene and breast cancer survival. International Journal of Cancer, 2009, 124, 208-214.	5.1	39
16	Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. American Journal of Human Genetics, 2015, 97, 22-34.	6.2	37
17	Gene expression in triple-negative breast cancer in relation to survival. Breast Cancer Research and Treatment, 2018, 171, 199-207.	2.5	35
18	Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer. Oncotarget, 2015, 6, 21353-21368.	1.8	35

#	Article	IF	Citations
19	Incidence and mortality of gynaecological cancers: Secular trends in urban Shanghai, China over 40 years. European Journal of Cancer, 2016, 63, 1-10.	2.8	34
20	Dietary B vitamin and methionine intakes and lung cancer risk among female never smokers in China. Cancer Causes and Control, 2012, 23, 1965-1975.	1.8	33
21	Use of nonsteroidal anti-inflammatory drugs and reduced breast cancer risk among overweight women. Breast Cancer Research and Treatment, 2014, 146, 439-446.	2.5	33
22	Contraceptive methods and ovarian cancer risk among Chinese women: A report from the Shanghai Women's Health Study. International Journal of Cancer, 2015, 137, 607-614.	5.1	31
23	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Research, 2016, 18, 64.	5.0	31
24	Matrix Metalloproteinase-2Polymorphisms and Breast Cancer Susceptibility. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1770-1776.	2.5	30
25	Melatonin pathway genes and breast cancer risk among Chinese women. Breast Cancer Research and Treatment, 2012, 132, 693-699.	2.5	30
26	CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes. Gynecologic Oncology, 2020, 157, 405-410.	1.4	30
27	Associations of Hormone-Related Factors With Breast Cancer Risk According to Hormone Receptor Status Among White and African American Women. Clinical Breast Cancer, 2014, 14, 417-425.	2.4	27
28	Chemokine Network and Overall Survival inTP53Wild-Type and Mutant Ovarian Cancer. Immune Network, 2018, 18, e29.	3.6	27
29	Identifying Putative Susceptibility Genes and Evaluating Their Associations with Somatic Mutations in Human Cancers. American Journal of Human Genetics, 2019, 105, 477-492.	6.2	27
30	Platelets, Thrombocytosis, and Ovarian Cancer Prognosis: Surveying the Landscape of the Literature. International Journal of Molecular Sciences, 2020, 21, 8169.	4.1	27
31	RAD51B in Familial Breast Cancer. PLoS ONE, 2016, 11, e0153788.	2.5	26
32	Genetic Variation in VEGF Family Genes and Breast Cancer Risk: A Report from the Shanghai Breast Cancer Genetics Study. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 33-41.	2.5	24
33	Fine-Scale Mapping of the 4q24 Locus Identifies Two Independent Loci Associated with Breast Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1680-1691.	2.5	24
34	Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer. Cancer Discovery, 2022, 12, 303-330.	9.4	24
35	MMP9 polymorphisms and breast cancer risk: a report from the Shanghai Breast Cancer Genetics Study. Breast Cancer Research and Treatment, 2011, 126, 507-513.	2.5	23
36	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	2.8	23

#	Article	IF	Citations
37	Early onset pancreatic malignancies: Clinical characteristics and survival associations. International Journal of Cancer, 2016, 139, 2169-2177.	5.1	22
38	Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. Cancer Causes and Control, 2016, 27, 679-693.	1.8	21
39	Increasing Area Deprivation Index negatively impacts ovarian cancer survival. Cancer Epidemiology, 2021, 74, 102013.	1.9	21
40	E-cadherin polymorphisms and breast cancer susceptibility: a report from the Shanghai Breast Cancer Study. Breast Cancer Research and Treatment, 2010, 121, 445-452.	2.5	19
41	Evaluation of Functional Genetic Variants for Breast Cancer Risk: Results From the Shanghai Breast Cancer Study. American Journal of Epidemiology, 2011, 173, 1159-1170.	3.4	18
42	Differential cyclooxygenase expression levels and survival associations in type I and type II ovarian tumors. Journal of Ovarian Research, 2018, 11, 17.	3.0	18
43	Interactions of Hormone Replacement Therapy, Body Weight, and Bilateral Oophorectomy in Breast Cancer Risk. Clinical Cancer Research, 2014, 20, 1169-1178.	7.0	17
44	Blood type, ABO genetic variants, and ovarian cancer survival. PLoS ONE, 2017, 12, e0175119.	2.5	17
45	Two-stage caseâ€“control study of DNMT-1 and DNMT-3B gene variants and breast cancer risk. Breast Cancer Research and Treatment, 2010, 121, 765-769.	2.5	15
46	CXCR2 is a negative regulator of p21 in p53-dependent and independent manner via Akt-mediated Mdm2 in ovarian cancer. Oncotarget, 2018, 9, 9751-9765.	1.8	15
47	No Association between Matrix Metalloproteinase-1 or Matrix Metalloproteinase-3 Polymorphisms and Breast Cancer Susceptibility: A Report from the Shanghai Breast Cancer Study. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1324-1327.	2.5	14
48	Ovarian Cancer in Women of African Ancestry (OCWAA) consortium: a resource of harmonized data from eight epidemiologic studies of African American and white women. Cancer Causes and Control, 2019, 30, 967-978.	1.8	14
49	Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. British Journal of Cancer, 2017, 116, 1223-1228.	6.4	13
50	IGF-II promoter specific methylation and expression in epithelial ovarian cancer and their associations with disease characteristics. Oncology Reports, 2011, 25, 203-13.	2.6	13
51	Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19. Blood Cancer Discovery, 2022, 3, 181-193.	5.0	12
52	Thresholds and timing of pre-operative thrombocytosis and ovarian cancer survival: analysis of laboratory measures from electronic medical records. BMC Cancer, 2016, 16, 612.	2.6	11
53	Prevalence of Anemia and Compliance With NCCN Guidelines for Evaluation and Treatment of Anemia in Patients With Gynecologic Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 513-520.	4.9	10
54	Replication study for reported SNP associations with breast cancer survival. Journal of Cancer Research and Clinical Oncology, 2012, 138, 1019-1026.	2.5	9

#	Article	IF	Citations
55	Racial disparities in epithelial ovarian cancer survival: An examination of contributing factors in the Ovarian Cancer in Women of African Ancestry consortium. International Journal of Cancer, 2022, 151, 1228-1239.	5.1	9
56	No Association between Matrix Metalloproteinase (MMP)-1, MMP-3, and MMP-7 SNPs and Endometrial Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1925-1928.	2.5	8
57	No association between genetic variants in angiogenesis and inflammation pathway genes and breast cancer survival among Chinese women. Cancer Epidemiology, 2013, 37, 619-624.	1.9	8
58	Associations of reproductive time events and intervals with breast cancer risk: A report from the Shanghai Breast Cancer Study. International Journal of Cancer, 2014, 135, 186-195.	5.1	8
59	Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium. Human Genetics, 2016, 135, 137-154.	3.8	8
60	Mammography use among women with and without diabetes: Results from the Southern Community Cohort Study. Journal of Epidemiology and Global Health, 2014, 4, 223.	2.9	7
61	Expression of p52, a non-canonical NF-kappaB transcription factor, is associated with poor ovarian cancer prognosis. Biomarker Research, 2020, 8, 45.	6.8	7
62	Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci. Oncotarget, 2017, 8, 64670-64684.	1.8	7
63	Energy-Related Indicators and Breast Cancer Risk among White and Black Women. PLoS ONE, 2015, 10, e0125058.	2.5	6
64	Obesity-Induced Peritoneal Dissemination of Ovarian Cancer and Dominant Recruitment of Macrophages in Ascites. Immune Network, 2018, 18, e47.	3.6	6
65	Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. Cancer Medicine, 2019, 8, 2503-2513.	2.8	6
66	Her-2/neu amplification and breast cancer survival: results from the Shanghai breast cancer study. Oncology Reports, 2008, 19, 1347-54.	2.6	6
67	Two truncating variants in FANCC and breast cancer risk. Scientific Reports, 2019, 9, 12524.	3.3	5
68	Identification of a Locus Near ULK1 Associated With Progression-Free Survival in Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1669-1680.	2.5	5
69	Urinary PGE-M Levels and Risk of Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1845-1852.	2.5	4
70	Racial Differences in Population Attributable Risk for Epithelial Ovarian Cancer in the OCWAA Consortium. Journal of the National Cancer Institute, 2021, 113, 710-718.	6.3	4
71	Firstâ€•and secondâ€degree family history of ovarian and breast cancer in relation to risk of invasive ovarian cancer in African American and white women. International Journal of Cancer, 2021, 148, 2964-2973.	5.1	4
72	High-Fat Diet-Induced Obese Effects of Adipocyte-Specific CXCR2 Conditional Knockout in the Peritoneal Tumor Microenvironment of Ovarian Cancer. Cancers, 2021, 13, 5033.	3.7	3

#	Article	IF	Citations
73	A pooled case-only analysis of obesity and breast cancer subtype among Black women in the southeastern United States. Cancer Causes and Control, 2022, 33, 515-524.	1.8	3
74	Genital Powder Use and Risk of Epithelial Ovarian Cancer in the Ovarian Cancer in Women of African Ancestry Consortium. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1660-1668.	2.5	2
75	The Impact of the Human Papillomavirus Vaccine on High-Grade Cervical Lesions in Urban and Rural Areas: An Ageâ€“Periodâ€“Cohort Analysis. Cancers, 2021, 13, 4215.	3.7	2
76	Evaluation of Information Theoretic Network Meta-analysis to Rank First-Line Anticancer Regimens for Hormone Receptorâ€“Positive, ERBB2-Negative Metastatic Breast Cancer. JAMA Network Open, 2022, 5, e224361.	5.9	2
77	Modeling the Impact of Delaying Bariatric Surgery due to COVID-19: a Decision Analysis. Obesity Surgery, 2021, 31, 1387-1391.	2.1	1
78	A gene expression prognostic signature for overall survival in patients with high-grade serous ovarian cancer.. Journal of Clinical Oncology, 2018, 36, 5583-5583.	1.6	1
79	Human Papillomavirus Vaccine Impact on Cervical Precancers in a Low-Vaccination Population. American Journal of Preventive Medicine, 2022, 62, 395-403.	3.0	1
80	Association of Leukocyte Adhesion and Rolling in Skin With Patient Outcomes After Hematopoietic Cell Transplantation Using Noninvasive Reflectance Confocal Videomicroscopy. JAMA Dermatology, 2022, , .	4.1	1
81	Race Differences in the Associations between Menstrual Cycle Characteristics and Epithelial Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 0, , OF1-OF11.	2.5	1
82	COVID-19 in patients with gynecologic cancer: A preliminary report from the COVID-19 and Cancer Consortium (CCC19).. Journal of Clinical Oncology, 2022, 40, 5508-5508.	1.6	0